[Skip to Navigation]
Views 987
Citations 0
Editorial
October 11, 2021

Avoidant Restrictive Food Intake Disorder—What Are We Missing? What Are We Waiting for?

Author Affiliations
  • 1Department of Adolescent Medicine, Tufts Children’s Hospital, Boston, Massachusetts
  • 2Department of Pediatrics, Public Health and Community Medicine, Boston, Massachusetts
JAMA Pediatr. Published online October 11, 2021. doi:10.1001/jamapediatrics.2021.3858

The diagnosis of avoidant restrictive food intake disorder (ARFID) materialized with the 2013 publication of the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) (DSM-5) by the American Psychiatric Association.1 Simply stated, ARFID is an eating or feeding disturbance characterized by lack of interest in or avoidance of food that results in inadequate weight or weight loss, significant nutritional deficiency, dependence on supplemental nutrition or alternative feeding methods, and marked interference with psychosocial functioning. Avoidant restrictive food intake disorder is aversion or phobia that may have a triggering event. It is not picky eating, adherence to a culturally sanctioned practice, or lack of available of nutritious food sources, and it is not about weight or body image. The weight and body image omission is an important feature that distinguishes it from other eating disorders (EDs) and their treatments. The DSM-5 does not provide a greater context of the scope of the problem, other epidemiologic information, or treatment options. Before the DSM-5 criteria, practitioners attempted to recognize and develop treatments for EDs that did not fit neatly into other diagnostic categories. With new diagnoses, practitioners may recognize more individuals with ARFID; however, they may struggle to screen for or treat these individuals because little evidence is available on ARFID-specific methods. Because ARFID is distinct from other EDs, we cannot simply apply clinical practices from other EDs. With the increase in ARFID diagnoses, it has become imperative that we develop a body of ARFID-specific data and evidence-based methods of screening and treatment for early detection, treatment, and optimization of health outcomes.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×